Amneal Pharmaceuticals, Class Stock Performance
| AMRX Stock | USD 8.44 0.08 0.94% |
On a scale of 0 to 100, Amneal Pharmaceuticals, holds a performance score of 14. The firm shows a Beta (market volatility) of 1.86, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Amneal Pharmaceuticals, will likely underperform. Please check Amneal Pharmaceuticals,'s treynor ratio, as well as the relationship between the expected short fall and day median price , to make a quick decision on whether Amneal Pharmaceuticals,'s price patterns will revert.
Risk-Adjusted Performance
14 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Amneal Pharmaceuticals, Class are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, Amneal Pharmaceuticals, showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.94) | Five Day Return (3.98) | Year To Date Return 41.14 | Ten Year Return (65.28) | All Time Return 77.68 |
1 | Disposition of 17497336 shares by Gautam Patel of Amneal Pharmaceuticals subject to Rule 16b-3 | 07/24/2024 |
2 | Wall Streets Insights Into Key Metrics Ahead of Amneal Q2 Earnings | 08/07/2024 |
3 | Compared to Estimates, Amneal Q2 Earnings A Look at Key Metrics | 08/09/2024 |
4 | Disposition of 100000 shares by Nikita Shah of Amneal Pharmaceuticals, at 7.75 subject to Rule 16b-3 | 08/14/2024 |
5 | Disposition of 40225 shares by Andrew Boyer of Amneal Pharmaceuticals, at 7.85 subject to Rule 16b-3 | 08/15/2024 |
6 | Despite Fast-paced Momentum, Amneal Is Still a Bargain Stock | 08/21/2024 |
7 | Acquisition by Konidaris Tasos of 175926 shares of Amneal Pharmaceuticals, subject to Rule 16b-3 | 08/28/2024 |
8 | Disposition of 76453 shares by Jeffrey George of Amneal Pharmaceuticals, subject to Rule 16b-3 | 08/30/2024 |
9 | Amneal and Shilpa Announce U.S. FDA Approval of BORUZU, the First Ready-to-Use Version of Bortezomib for subcutaneous administration | 09/05/2024 |
10 | Amneal Launches CREXONT Extended-Release Capsules for Treatment of Parkinsons Disease | 09/23/2024 |
| Begin Period Cash Flow | 35.2 M |
Amneal |
Amneal Pharmaceuticals, Relative Risk vs. Return Landscape
If you would invest 642.00 in Amneal Pharmaceuticals, Class on June 27, 2024 and sell it today you would earn a total of 202.00 from holding Amneal Pharmaceuticals, Class or generate 31.46% return on investment over 90 days. Amneal Pharmaceuticals, Class is currently generating 0.4719% in daily expected returns and assumes 2.5106% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Amneal, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Amneal Pharmaceuticals, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amneal Pharmaceuticals,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Amneal Pharmaceuticals, Class, and traders can use it to determine the average amount a Amneal Pharmaceuticals,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1879
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AMRX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.51 actual daily | 22 78% of assets are more volatile |
Expected Return
| 0.47 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.19 actual daily | 14 86% of assets perform better |
Based on monthly moving average Amneal Pharmaceuticals, is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Amneal Pharmaceuticals, by adding it to a well-diversified portfolio.
Amneal Pharmaceuticals, Fundamentals Growth
Amneal Stock prices reflect investors' perceptions of the future prospects and financial health of Amneal Pharmaceuticals,, and Amneal Pharmaceuticals, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Amneal Stock performance.
| Return On Equity | -1.49 | ||||
| Return On Asset | 0.0609 | ||||
| Profit Margin | (0.07) % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 5.29 B | ||||
| Shares Outstanding | 309.54 M | ||||
| Price To Earning | 230.50 X | ||||
| Price To Book | 86.10 X | ||||
| Price To Sales | 1.01 X | ||||
| Revenue | 2.39 B | ||||
| Gross Profit | 791.46 M | ||||
| EBITDA | 417.96 M | ||||
| Net Income | (48.72 M) | ||||
| Cash And Equivalents | 87.33 M | ||||
| Cash Per Share | 0.58 X | ||||
| Total Debt | 2.75 B | ||||
| Current Ratio | 1.74 X | ||||
| Book Value Per Share | (0.19) X | ||||
| Cash Flow From Operations | 345.58 M | ||||
| Earnings Per Share | (0.79) X | ||||
| Market Capitalization | 2.61 B | ||||
| Total Asset | 3.47 B | ||||
| Retained Earnings | (490.18 M) | ||||
| Working Capital | 531.27 M | ||||
| Current Asset | 753.39 M | ||||
| Current Liabilities | 310.2 M | ||||
About Amneal Pharmaceuticals, Performance
Evaluating Amneal Pharmaceuticals,'s performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Amneal Pharmaceuticals, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Amneal Pharmaceuticals, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 134.90 | 182.25 | |
| Return On Tangible Assets | (0.04) | (0.04) | |
| Return On Capital Employed | 0.08 | 0.12 | |
| Return On Assets | (0.02) | (0.02) | |
| Return On Equity | (4.25) | (4.03) |
Things to note about Amneal Pharmaceuticals, performance evaluation
Checking the ongoing alerts about Amneal Pharmaceuticals, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Amneal Pharmaceuticals, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 2.39 B. Net Loss for the year was (48.72 M) with profit before overhead, payroll, taxes, and interest of 791.46 M. | |
| Amneal Pharmaceuticals, has a strong financial position based on the latest SEC filings | |
| About 54.0% of the company shares are held by company insiders | |
| Latest headline from businesswire.com: Amneal Launches CREXONT Extended-Release Capsules for Treatment of Parkinsons Disease |
- Analyzing Amneal Pharmaceuticals,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Amneal Pharmaceuticals,'s stock is overvalued or undervalued compared to its peers.
- Examining Amneal Pharmaceuticals,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Amneal Pharmaceuticals,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Amneal Pharmaceuticals,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Amneal Pharmaceuticals,'s stock. These opinions can provide insight into Amneal Pharmaceuticals,'s potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.